|
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
Jan 2019 |
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
|
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium |
Dec 2020 |
Cancer Medicine |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience |
Nov 2020 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases |
Apr 2023 |
Internal and Emergency Medicine |
Myelodysplastic Syndromes (MDS) |
|
What causes aplastic anaemia? |
Apr 2023 |
Leukemia |
Aplastic Anemia |
|
Where There's Smoke, There's Fire: Inflammation Drives MDS |
Jul 2020 |
Trends in immunology |
Myelodysplastic Syndromes (MDS) |
|
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study |
Apr 2023 |
Journal of Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS |
Jul 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
